Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 7/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877004 | 0.80 | AKT1S1 (0.41) | AKT1S1ROCK2ROCK1CDC42BPBHRH3 | |
| SCHEMBL7406379 | 0.79 | NCF1 (0.49) | NCF1ADRB2ROCK2ROCK1CDC42BPB | |
| SCHEMBL31599929 | 0.75 | ROCK2 (0.46) | AKT1S1ROCK2ROCK1CDC42BPBHRH3 | |
| SCHEMBL2800011 | 0.75 | AKT1S1 (0.53) | AKT1S1HTR2C | |
| SCHEMBL21935475 | 0.75 | DDB1 (0.44) | AKT1S1 | |
| Hydrochloric Acid SCHEMBL2797277 | 0.74 | AKT1S1 (0.52) | AKT1S1HTR2C | |
| SCHEMBL13533073 | 0.73 | DRD2 (0.55) | NCF1HTR2AHTR2CSLC6A4ADRB1 | |
| SCHEMBL21919667 | 0.71 | NCF1 (0.47) | NCF1ADRB2ROCK2ROCK1CDC42BPB | |
| SCHEMBL17041865 | 0.71 | UHRF1 (0.55) | AKT1S1HTR2AHTR2C | |
| SCHEMBL31600294 | 0.71 | PRKCI (0.40) | AKT1S1ROCK2ROCK1HTR2CPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | AKT1S1 1499/4885NCF1 586/4885ADRB2 3638/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | AKT1S1 1499/4885NCF1 586/4885ADRB2 3638/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | AKT1S1 1499/4885NCF1 586/4885ADRB2 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.